NEW YORK, August 10, 2026, 04:12 EDT —
- Shares rose 27.5% last week, ending Friday at $82.83.
- The action generated approximately $10.7 billion in equity value ahead of Monday’s report.
- Analysts on average project revenue of $231.62 million and a per-share loss of $0.06.
Rocket Lab gained approximately $10.7 billion in market capitalization last week, ahead of its second-quarter earnings release set for Monday. The stock advanced 27.5% between July 31 and the end of trading on Friday.
The rise over the week matched 4.8 times the value of Rocket Lab’s backlog as of the end of March. The company disclosed $2.22 billion in contracted work yet to be fulfilled. Just 36% was anticipated to turn into revenue within a year.
Backlog and market value measure different things. The comparison instead highlights the magnitude of last week’s revaluation. Investors are now paying significantly above the value of existing contracts.
With 598.18 million shares and $679.58 million in trailing revenue, the contrast is notable. The figures are based on the most recent share count for each date.
| Valuation measure | July 31 | August 7 | One-week change |
|---|---|---|---|
| Closing price | $64.95 | $82.83 | +27.5% |
| Approximate equity value | $38.85 billion | $49.55 billion | +$10.70 billion |
| Equity value/trailing revenue | 57.2 times | 72.9 times | +15.7 turns |
Nasdaq’s main session finished prior to the dateline. Trading before the market officially opened began at 4 a.m. EDT. An initial quote at 04:04 EDT displayed $85.70, a rise of 3.5%. Liquidity during extended-hours trading is generally lower.
The average forecast points to second-quarter revenue of $231.62 million. Analysts are projecting a per-share loss of $0.06. The revenue estimate closely aligns with the midpoint of Rocket Lab’s own guidance of $232.5 million.
| Earnings measure | Q2 2025 actual | Q1 2026 actual | Q2 2026 company guidance | Q2 2026 preliminary consensus |
|---|---|---|---|---|
| Revenue | $144.50 million | $200.35 million | $225 million-$240 million | $231.62 million |
| EPS | $(0.13) | $(0.07) | — | $(0.06) |
| GAAP gross margin | — | 38.2% | 33%-35% | — |
| Adjusted EBITDA loss | — | — | $20 million-$26 million | — |
Consensus estimates point to revenue rising 60.3% from the prior year, and up 15.6% compared to the previous quarter. Margin is more challenging; company guidance is set three to five percentage points under Q1.
Last week brought new operational updates. Rocket Lab secured a $397 million contract from the U.S. Space Force. In addition, the company carried out its 92nd Electron launch for iQPS, a subsidiary of QPS Holdings (TYO:464A).
| Date | Development | Verified scale | Investor relevance |
|---|---|---|---|
| August 4 | SB-AMTI contract won by Space Force | $397 million, including an option | Focus on Neutron project progress and contract schedule |
| August 6 | Deployment of QPS-SAR-13 | 92nd Electron launch; 13th Electron launch for 2026 | Importance of launch frequency and recurring demand |
| Later in August | Upcoming Electron launch for iQPS | Scheduled additional QPS-SAR deployment | Evidence of ability to maintain steady launch rate |
Chief Executive Peter Beck stated that Rocket Lab’s integrated approach “uniquely position us to deliver innovative solutions.” The contract includes spacecraft, operations, and launch services. It also connects some of Rocket Lab’s growth outlook to Neutron. In May, Rocket Lab set the rocket’s inaugural launch for later in 2026. markets.businessinsider.com
Electron provides a reliable balancing option. The rocket completed its 13th mission of the year on Thursday, marking iQPS’s eighth flight. iQPS has secured ten further exclusive launches on Electron scheduled up to 2030.
Wall Street sentiment is upbeat, though target estimates vary significantly. According to MarketBeat, analysts issued 16 buy ratings, five holds, and one sell. The consensus price target is $110.29, suggesting 33.2% potential upside from Friday’s close.
| Date | Firm and analyst | Recommendation | Target | Upside versus $82.83 |
|---|---|---|---|---|
| Current compilation | 22-analyst consensus | Moderate Buy | $110.29 | 33.2% |
| July 15 | Piper Sandler NYSE:PIPR, Alexander Potter | Neutral | $83 | 0.2% |
| June 30 | Cantor Fitzgerald, Andres Sheppard | Overweight | $96 | 15.9% |
| June 30 | Needham, Ryan Koontz | Buy | $120 | 44.9% |
| June 29 | Roth Capital, Suji Desilva | Buy | $130 | 56.9% |
Monday’s earnings are released after the market closes. The company will hold a conference call at 5 p.m. EDT. Investors are focusing on revenue, GAAP margin, backlog details, and Neutron updates.
Risks: The value of contracts is recognized upon milestone achievements rather than at the time awards are disclosed. The $397 million contract total factors in an option. Revenue timing may be affected if Neutron experiences further delays, and the 72.9-times sales multiple amplifies the effect of any shortfall.
Launch activity remains robust. With the current valuation, the primary focus shifts to backlog conversion.
Related articles: NASDAQ:RKLB
